The treatment of<unk>  C has changed dramatically over the past decade.  Although protease inhibitors Telaprevir and Boceprevir are often combined with the regular regimen of IFN and Ribavirin to treat patients with genotype 1 HCV, Sofosbuvir and Simeprevir have demonstrated greater efficacy in viral clearance along with a better safety profile. Guidelines from the AASLD and the IDSA have recommended the use of these oral agents (particularly Sofosbuvir) as first-line agents in the treatment of chronic HCV among both relapsers and treatment-naive patients.
Hepatitis C medical therapy
Hepatitis B medical therapy
Hepatitis D medical therapy
Hepatitis E medical therapy
Autoimmune hepatitis medical therapy
Alcoholic hepatitis medical therapy
Hepatitis C secondary prevention
Fatty liver medical therapy